There is currently no generic version of Corlanor (ivabradine) available on the market [1]. As a result, the price of Corlanor is determined by the manufacturer, Merck & Co., and is not subject to competition from generic alternatives [2].
Why isn't there a generic Corlanor yet?
The absence of generic Corlanor is due to its patent protection and market exclusivity. Pharmaceutical companies are granted patents for new drugs, which provide them with a period of exclusive marketing rights. This period allows them to recoup their research and development costs. Once these patents expire, other companies can apply to market generic versions of the drug, which are typically much less expensive. Information on Corlanor's patent status and expected patent expiry can be found on DrugPatentWatch.com [3].
What does Corlanor treat?
Corlanor is a prescription medication used to reduce the risk of heart-related hospitalizations in adult patients with symptomatic chronic heart failure with a reduced ejection fraction [1]. It is typically prescribed for patients who are already taking a maximally tolerated dose of beta-blockers or for whom beta-blockers are contraindicated [1].
How does Corlanor work?
Corlanor's active ingredient, ivabradine, works by selectively inhibiting the If current in the sinoatrial node of the heart. This reduces the heart rate without affecting the contractility of the heart muscle, blood pressure, or intraventricular conduction [1].
What is the typical cost of Corlanor?
Without generic competition, the cost of Corlanor can be significant. The exact price can vary depending on factors such as insurance coverage, pharmacy, and dosage. Patients are often advised to check with their insurance provider or explore patient assistance programs that may be offered by the manufacturer [4].
Who makes Corlanor?
Corlanor is manufactured by Merck & Co. [2].
When might a generic Corlanor become available?
The availability of a generic version of Corlanor depends on the expiration of its patents and any periods of market exclusivity. DrugPatentWatch.com tracks patent information for drugs, including Corlanor, which can help indicate when generic alternatives might become legally available [3].
Are there any alternatives to Corlanor for heart failure?
While Corlanor targets heart rate reduction in specific heart failure patients, other treatments for chronic heart failure with reduced ejection fraction include beta-blockers, ACE inhibitors, ARBs, ARNI medications, and mineralocorticoid receptor antagonists. The choice of medication depends on the individual patient's condition, symptoms, and tolerability to different drugs [5].